Literature DB >> 1577950

In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis.

M K Sharief1, E J Thompson.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) has well recognized effects on cerebral endothelial cells and, therefore, may mediate disruption of blood-brain barrier in patients with multiple sclerosis (MS). To evaluate the in vivo relationship of TNF-alpha to blood-brain barrier impairment in MS, levels of this cytokine in cerebrospinal fluid (CSF) and serum samples from 38 patients with active MS and 48 controls were correlated with CSF to serum albumin ratios. TNF-alpha was detected in the serum of 74% and the CSF of 66% of patients with active MS. CSF levels of TNF-alpha were significantly higher in active MS compared to stable MS or other controls, and were significantly higher than corresponding serum levels. In patients with active MS, only those with detectable TNF-alpha showed signs of blood-brain barrier damage. Moreover, intrathecal levels of TNF-alpha in active MS correlated with albumin ratios and with the degree of barrier damage. Our findings are important in understanding some of the pathological changes in active multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1577950     DOI: 10.1016/0165-5728(92)90087-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  28 in total

Review 1.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Microglia mediate postoperative hippocampal inflammation and cognitive decline in mice.

Authors:  Xiaomei Feng; Martin Valdearcos; Yosuke Uchida; David Lutrin; Mervyn Maze; Suneil K Koliwad
Journal:  JCI Insight       Date:  2017-04-06

3.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

4.  Central inflammation versus peripheral regulation in multiple sclerosis.

Authors:  L J Edwards; B Sharrack; A Ismail; H Tumani; C S Constantinescu
Journal:  J Neurol       Date:  2011-03-09       Impact factor: 4.849

5.  Natural triterpenes modulate immune-inflammatory markers of experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis.

Authors:  R Martín; M Hernández; C Córdova; M L Nieto
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 6.  Cytokines, signal transduction, and inflammatory demyelination: review and hypothesis.

Authors:  R W Ledeen; G Chakraborty
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

7.  Use of human antigen presenting cell gene array profiling to examine the effect of human T-cell leukemia virus type 1 Tax on primary human dendritic cells.

Authors:  Jaya Ahuja; Karan Kampani; Suman Datta; Brian Wigdahl; Katherine E Flaig; Pooja Jain
Journal:  J Neurovirol       Date:  2006-02       Impact factor: 2.643

8.  Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.

Authors:  C E Shaw; P R Dunbar; H A Macaulay; T J Neale
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

9.  An analysis of peripheral type benzodiazepine receptors on blood mononuclear cells during high dose steroid treatment of multiple sclerosis.

Authors:  P Ferrero; P Rocca; P Benna; C De Leo; E Montalenti; L Ravizza; B Bergamasco
Journal:  Ital J Neurol Sci       Date:  1992-11

10.  Induction of pro-inflammatory cytokines by human T-cell leukemia virus type-1 Tax protein as determined by multiplexed cytokine protein array analyses of human dendritic cells.

Authors:  Jaya Ahuja; Veronique Lepoutre; Brian Wigdahl; Zafar K Khan; Pooja Jain
Journal:  Biomed Pharmacother       Date:  2007-03-07       Impact factor: 6.529

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.